Literature DB >> 29608954

Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain.

Daniela Belletti1, Andreas Martin Grabrucker2, Francesca Pederzoli1, Isabel Menrath3, Maria Angela Vandelli1, Giovanni Tosi1, Thomas Jason Duskey1, Flavio Forni1, Barbara Ruozi4.   

Abstract

Restoration of the Chol homeostasis in the Central Nervous System (CNS) could be beneficial for the treatment of Huntington's Disease (HD), a progressive, fatal, adult-onset, neurodegenerative disorder. Unfortunately, Chol is unable to cross the blood-brain barrier (BBB), thus a novel strategy for a targeted delivery of Chol into the brain is highly desired. This article aims to investigate the production of hybrid nanoparticles composed by Chol and PLGA (MIX-NPs) modified with g7 ligand for BBB crossing. We described the impact of ratio between components (Chol and PLGA) and formulation process (nanoprecipitation or single emulsion process) on physico-chemical and structural characteristics, we tested MIX-NPs in vitro using primary hippocampal cell cultures evaluating possible toxicity, uptake, and the ability to influence excitatory synaptic receptors. Our results elucidated that both formulation processes produce MIX-NPs with a Chol content higher that 40%, meaning that Chol is a structural particle component and active compound at the same time. The formulation strategy impacted the architecture and reorganization of components leading to some differences in Chol availability between the two types of g7 MIX-NPs. Our results identified that both kinds of MIX-NPs are efficiently taken up by neurons, able to escape lysosomes and release Chol into the cells resulting in an efficient modification in expression of synaptic receptors that could be beneficial in HD.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood brain barrier; Cholesterol; Nanoparticles; PLGA

Mesh:

Substances:

Year:  2018        PMID: 29608954     DOI: 10.1016/j.ijpharm.2018.03.061

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  2 in total

1.  Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments.

Authors:  Jason Thomas Duskey; Arianna Rinaldi; Ilaria Ottonelli; Riccardo Caraffi; Chiara Alessia De Benedictis; Ann Katrin Sauer; Giovanni Tosi; Maria Angela Vandelli; Barbara Ruozi; Andreas Martin Grabrucker
Journal:  Pharmaceutics       Date:  2022-07-12       Impact factor: 6.525

2.  Striatal infusion of cholesterol promotes dose-dependent behavioral benefits and exerts disease-modifying effects in Huntington's disease mice.

Authors:  Giulia Birolini; Marta Valenza; Eleonora Di Paolo; Elena Vezzoli; Francesca Talpo; Claudia Maniezzi; Claudio Caccia; Valerio Leoni; Franco Taroni; Vittoria D Bocchi; Paola Conforti; Elisa Sogne; Lara Petricca; Cristina Cariulo; Margherita Verani; Andrea Caricasole; Andrea Falqui; Gerardo Biella; Elena Cattaneo
Journal:  EMBO Mol Med       Date:  2020-09-22       Impact factor: 12.137

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.